Strong Vivian E, Gholami Sepideh, Shah Manish A, Tang Laura H, Janjigian Yelena Y, Schattner Mark, Selby Luke V, Yoon Sam S, Salo-Mullen Erin, Stadler Zsofia K, Kelsen David, Brennan Murray F, Coit Daniel G
*Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY †Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY ‡Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY §Department of Gastroenterology, Memorial Sloan Kettering Cancer Center, New York, NY ¶Department of Medicine, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Ann Surg. 2017 Dec;266(6):1006-1012. doi: 10.1097/SLA.0000000000002030.
OBJECTIVE: The aim of this study was to describe postoperative outcomes of total gastrectomy at our institution for patients with hereditary diffuse gastric cancer (HDGC). BACKGROUND: HDGC, which is mainly caused by germline mutations in the E-cadherin gene (CDH1), renders a lifetime risk of gastric cancer of up to 70%, prompting a recommendation for prophylactic total gastrectomy. METHODS: A prospective gastric cancer database identified 41 patients with CDH1 mutation who underwent total gastrectomy during 2005 to 2015. Perioperative, histopathologic, and long-term data were collected. RESULTS: Of the 41 patients undergoing total gastrectomy, median age was 47 years (range 20 to 71). There were 14 men and 27 women, with 25 open operations and 16 minimally invasive operations. Median length of stay was 7 days (range 4 to 50). In total, 11 patients (27%) experienced a complication requiring intervention, and there was 1 peri-operative mortality (2.5%). Thirty-five patients (85%) demonstrated 1 or more foci of intramucosal signet ring cell gastric cancer in the examined specimen. At 16 months median follow-up, the median weight loss was 4.7 kg (15% of preoperative weight). By 6 to 12 months postoperatively, weight patterns stabilized. Overall outcome was reported to be "as expected" by 40% of patients and "better than expected" by 45%. Patient-reported outcomes were similar to those of other patients undergoing total gastrectomy. CONCLUSION: Total gastrectomy should be considered for all CDH1 mutation carriers because of the high risk of invasive diffuse-type gastric cancer and lack of reliable surveillance options. Although most patients have durable weight loss after total gastrectomy, weights stabilize at about 6 to 12 months postoperatively, and patients report outcomes as being good to better than their preoperative expectations. No patients have developed gastric cancer recurrence after resections.
目的:本研究旨在描述我院对遗传性弥漫性胃癌(HDGC)患者行全胃切除术后的结局。 背景:HDGC主要由E-钙黏蛋白基因(CDH1)的种系突变引起,其患胃癌的终生风险高达70%,因此建议行预防性全胃切除术。 方法:通过前瞻性胃癌数据库确定了2005年至2015年间41例因CDH1突变而行全胃切除术的患者。收集围手术期、组织病理学和长期数据。 结果:41例行全胃切除术的患者中,中位年龄为47岁(范围20至71岁)。男性14例,女性27例,其中25例为开放手术,16例为微创手术。中位住院时间为7天(范围4至50天)。共有11例患者(27%)出现需要干预的并发症,围手术期死亡1例(2.5%)。35例患者(85%)的检查标本中显示有1个或更多黏膜内印戒细胞型胃癌病灶。中位随访16个月时,中位体重减轻4.7kg(占术前体重的15%)。术后6至12个月时,体重模式趋于稳定。40%的患者报告总体结局“与预期相符”,45%的患者报告“好于预期”。患者报告的结局与其他行全胃切除术的患者相似。 结论:由于侵袭性弥漫型胃癌风险高且缺乏可靠的监测方法,所有CDH1突变携带者均应考虑行全胃切除术。虽然大多数患者在全胃切除术后体重持续减轻,但术后约6至12个月体重趋于稳定,且患者报告结局良好至好于术前预期。切除术后无患者发生胃癌复发。
J Laparoendosc Adv Surg Tech A. 2021-7
Ned Tijdschr Geneeskd. 2003-12-13
Ann Surg Oncol. 2011-3-18
J Gastrointest Surg. 2025-1
Ann Surg Oncol. 2024-6